BioCentury | Jan 22, 2009
Distillery Therapeutics

Indication: Neurology

...the hybrid compound synthesis, testing the compounds in mouse models of AD and determining bioavailability. Neuro-Hitech Inc.'s...
BioCentury | Nov 24, 2008
Company News

Neuro-Hitech deal

...In exchange for $1.3 million in inventory credit and elimination of $6 million in debt, Neuro-Hitech...
...shares to David Ambrose, the sole shareholder of AMBI Pharmaceuticals Inc. and MCR Pharmaceuticals Inc. Neuro-Hitech...
...a 50.1% stake in Neuro-Hitech, was appointed vice chairman and may appoint two additional directors. Neuro-Hitech Inc....
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech board of directors update

Neuro-Hitech Inc. (OTCBB:NHPI), New York, N.Y. Business: Neurology Appointed: Phillip Young, president and CEO of Osteologix Inc. ; and Kevin Esval, president of VelocityHealth Securities Inc. Departed: Gary Shearman; Jay Lombard; and Alan Kestenbaum WIR...
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech management update

Neuro-Hitech Inc. (OTCBB:NHPI), New York, N.Y. Business: Neurology Hired: Matt Colpoys as president, CEO and a director, formerly VP of marketing and sales at Insmed Inc. ; he replaces Gary Shearman, who resigned WIR Staff...
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech, AMBI Pharmaceuticals Inc., MCR American Pharmaceuticals Inc. deal

...due on June 6, 2010; and 3 million shares worth about $1.4 million based on Neuro-Hitech’s...
...AMBI and MCR had combined revenues of about $2.7 million. Velocity Health Securities advised MCR. Neuro-Hitech...
...$9 million. Separately, Neuro-Hitech raised $3.0 million in a private offering of 12.1 million shares. Neuro-Hitech Inc....
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...a Phase III trial (Study C119) to treat pain associated with HIV-distal sensory polyneuropathy (HIV-DSP) Neuro-Hitech...
BioCentury | Feb 4, 2008
Clinical News

Huperzine A: Phase II data

...high-dose group did show a trend towards improvement on the latter endpoint vs. placebo (p=0.077). Neuro-Hitech Inc....
BioCentury | Feb 4, 2008
Finance

Ebb & Flow

...an antihistamine in Russia (see B20). Medivation finished the week up $1.47 (10%) to $16.32. Neuro-Hitech...
...from the Huperzia serrata herb also failed to show significance on the study's secondary endpoints. Neuro-Hitech...
BioCentury | Feb 2, 2008
Clinical News

Neuro-Hitech falls on AD data

Neuro-Hitech (NASDAQ:NHPI) fell $1.99 (68%) to $0.93 on Friday after Huperzine A missed the primary endpoint of a significant improvement in ADAS-Cog scores for the low-dose group (200 ug twice daily) vs. placebo at week...
BioCentury | Oct 29, 2007
Company News

Artisan Pharma board of directors update

...Artisan Pharma Inc. , Waltham, Mass. Business: Cardiovascular Appointed: Gary Shearman, president and CEO of Neuro-Hitech Inc. WIR...
Items per page:
1 - 10 of 23
BioCentury | Jan 22, 2009
Distillery Therapeutics

Indication: Neurology

...the hybrid compound synthesis, testing the compounds in mouse models of AD and determining bioavailability. Neuro-Hitech Inc.'s...
BioCentury | Nov 24, 2008
Company News

Neuro-Hitech deal

...In exchange for $1.3 million in inventory credit and elimination of $6 million in debt, Neuro-Hitech...
...shares to David Ambrose, the sole shareholder of AMBI Pharmaceuticals Inc. and MCR Pharmaceuticals Inc. Neuro-Hitech...
...a 50.1% stake in Neuro-Hitech, was appointed vice chairman and may appoint two additional directors. Neuro-Hitech Inc....
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech board of directors update

Neuro-Hitech Inc. (OTCBB:NHPI), New York, N.Y. Business: Neurology Appointed: Phillip Young, president and CEO of Osteologix Inc. ; and Kevin Esval, president of VelocityHealth Securities Inc. Departed: Gary Shearman; Jay Lombard; and Alan Kestenbaum WIR...
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech management update

Neuro-Hitech Inc. (OTCBB:NHPI), New York, N.Y. Business: Neurology Hired: Matt Colpoys as president, CEO and a director, formerly VP of marketing and sales at Insmed Inc. ; he replaces Gary Shearman, who resigned WIR Staff...
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech, AMBI Pharmaceuticals Inc., MCR American Pharmaceuticals Inc. deal

...due on June 6, 2010; and 3 million shares worth about $1.4 million based on Neuro-Hitech’s...
...AMBI and MCR had combined revenues of about $2.7 million. Velocity Health Securities advised MCR. Neuro-Hitech...
...$9 million. Separately, Neuro-Hitech raised $3.0 million in a private offering of 12.1 million shares. Neuro-Hitech Inc....
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...a Phase III trial (Study C119) to treat pain associated with HIV-distal sensory polyneuropathy (HIV-DSP) Neuro-Hitech...
BioCentury | Feb 4, 2008
Clinical News

Huperzine A: Phase II data

...high-dose group did show a trend towards improvement on the latter endpoint vs. placebo (p=0.077). Neuro-Hitech Inc....
BioCentury | Feb 4, 2008
Finance

Ebb & Flow

...an antihistamine in Russia (see B20). Medivation finished the week up $1.47 (10%) to $16.32. Neuro-Hitech...
...from the Huperzia serrata herb also failed to show significance on the study's secondary endpoints. Neuro-Hitech...
BioCentury | Feb 2, 2008
Clinical News

Neuro-Hitech falls on AD data

Neuro-Hitech (NASDAQ:NHPI) fell $1.99 (68%) to $0.93 on Friday after Huperzine A missed the primary endpoint of a significant improvement in ADAS-Cog scores for the low-dose group (200 ug twice daily) vs. placebo at week...
BioCentury | Oct 29, 2007
Company News

Artisan Pharma board of directors update

...Artisan Pharma Inc. , Waltham, Mass. Business: Cardiovascular Appointed: Gary Shearman, president and CEO of Neuro-Hitech Inc. WIR...
Items per page:
1 - 10 of 23